<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="367719">
  <stage>Registered</stage>
  <submitdate>10/01/2015</submitdate>
  <approvaldate>27/03/2015</approvaldate>
  <actrnumber>ACTRN12615000288527</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of epidural Dexmedetomidine as analgesic adjunct to local anesthetic in patients undergoing major abdominal cancer surgery</studytitle>
    <scientifictitle>In major abdominal cancer surgery, does epidural dexmedetomidine added to bupivacaine, compared to epidural bupivacaine only, reduce postoperative opioid consumption?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-operative pain following major abdominal cancer surgery.</healthcondition>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Anaesthetics</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Any cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Surgery</conditioncode1>
      <conditioncode2>Other surgery</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Before induction of anesthesia (pre-incision), for group BD, we will give epidural bolous dose of Dexmedetomidine 0.2 mic /kg added to 0.1 ml /kg of Bupivacaine 0.125%, then, we will give epidural infusion of Dexmedetomidine 0.2 mic /kg /h added to 0.1 ml /kg/h of Bupivacaine 0.125%  for 48 h postoperatively . for group B, we will give epidural bolous dose of 0.1 ml /kg Bupivacaine 0.125%, then, we will give epidural infusion of 0.1 ml /kg/h of Bupivacaine 0.125%  for 48 h postoperatively.  </interventions>
    <comparator>For group B (control group) we will give epidural bolous dose of 0.1 ml /kg Bupivacaine 0.125%, then, we will give epidural infusion of 0.1 ml /kg/h of Bupivacaine 0.125%  for 48 h postoperatively.  </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>postoperative opioid consumption of patients recorded by research nurse.</outcome>
      <timepoint>48 hours postoperatively</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>pain intensity by visual analogue scale</outcome>
      <timepoint>pain intensity by visual analogue scale assessed at 2h, 4 h, 8 h, 16 h, 24 h, 36 h and  48 h postoperatively</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>patients with  physical status American Society of Anaesthesiologist (ASA) I , II and III who will undergo major abdominal cancer surgery will be enrolled into the study. </inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with coagulation abnormalities, spinal deformities, and patients allergic to amide type of local anesthetics or Dexmedetomidine will be   excluded from the study. </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>25/01/2015</anticipatedstartdate>
    <actualstartdate>25/01/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate>20/01/2016</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>60</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>diab fuad hetta</primarysponsorname>
    <primarysponsoraddress>10 soliman hakeem street, assuit city, 71111,  egypt
organization address: south egypt cancer institute, 2 el methaque st., assuit city, 71111,  egypt</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>diab fuad hetta</fundingname>
      <fundingaddress>10 soliman hakeem street, assuit city, 71111,  egypt
</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>noha esmail ibrahim</sponsorname>
      <sponsoraddress>10 soliman hakeem street, assuit city, 71111,  egypt
organization address: faculty of medicine, 1 university st., assuit city, 71111,  egypt</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>evaluation of analgesic efficacy of epiduraly administered dexmedetomidine when given as analgesic adjunct to bupivacaine 0.125% in postoperative period after major abdominal cancer surgery.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Egypt Cancer institute-IRB IORG0006563</ethicname>
      <ethicaddress>South Egypt Cancer institute, 2 El methaque street, 71111, Assuit city, Egypt.</ethicaddress>
      <ethicapprovaldate>11/01/2015</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>10 soliman hakeem street, assuit city, 71111,  egypt
organization address: south egypt cancer institute, 2 el methaque st., assuit city, 71111,  egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta@gmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>10 soliman hakeem street, assuit city, 71111,  egypt
organization address: south egypt cancer institute, 2 el methaque st., assuit city, 71111,  egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta@gmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>diab fuad hetta</name>
      <address>10 soliman hakeem street, assuit city, 71111,  egypt
organization address: south egypt cancer institute, 2 el methaque st., assuit city, 71111,  egypt</address>
      <phone>+201091090009</phone>
      <fax />
      <email>diabhetta@gmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>